Alkylator
Thiotepa
Tepadina · TT
A small alkylator whose urothelial bite shows up as hemorrhagic cystitis, not tubular injury.
MildAlkylator · approved 1959
Stem cell transplant conditioning (e.g., thiotepa-busulfan-fludarabine)Breast and ovarian cancerCNS lymphoma/leptomeningeal disease (intrathecal)Superficial bladder cancer (intravesical)
Signature kidney injury
Hemorrhagic Cystitis
Hemorrhagic cystitis is a recognized complication of alkylator-based conditioning; thiotepa-containing (thiotepa-busulfan-fludarabine) regimens are associated with higher HC risk, with overall post-transplant HC reported in roughly the 12-37% range across regimens and confounded by viral reactivation.
Source: Galli et al., Eur J Haematol 2024
Mechanism of kidney injury
Thiotepa and its active metabolite TEPA are excreted in urine, where reactive alkylating species injure the bladder urothelium, causing mucosal inflammation, ulceration and hemorrhage (hemorrhagic cystitis). The parent drug is partly renally cleared and renal impairment increases thiotepa/TEPA exposure, but direct tubular nephrotoxicity is not the dominant lesion. BK/JC polyomavirus reactivation frequently co-contributes to HC in the transplant setting.
Clinical presentation
Dysuria, urinary frequency, and hematuria ranging from microscopic to gross with clots; suprapubic/bladder pain. Renal function is usually preserved unless clot obstruction causes post-renal AKI.
Onset
Early HC during/after conditioning; later HC with viral (BK/JC) reactivation.
Reversibility
Reversible
Anticancer mechanism
Polyfunctional aziridine alkylating agent that cross-links DNA; small and lipophilic, it penetrates the CNS well. Used in high-dose transplant conditioning regimens (e.g., TBF), for CNS and breast/ovarian malignancies, and intravesically for superficial bladder cancer.
Management
Hydration, continuous bladder irrigation for clots, and treatment of contributing viral infection; severe cases may need cystoscopic clot evacuation or fulguration. Most hemorrhagic cystitis resolves with supportive care.
Risk factors
- Multi-alkylator conditioning (thiotepa + busulfan + fludarabine; cyclophosphamide)
- HLA-mismatched / male recipients
- BK/JC viruria in transplant
- Renal impairment (increased thiotepa/TEPA exposure)
Prevention
- Hyperhydration and bladder protection during conditioning
- Mesna with concurrent oxazaphosphorines (cyclophosphamide/ifosfamide)
- Monitor for and manage viral reactivation
Note · The renal-tract signature is urothelial (hemorrhagic cystitis), usually in multi-agent conditioning where attributing risk to thiotepa alone is difficult; renal impairment is a dosing/exposure concern rather than a tubular-toxicity one.
Clinical depth
Renal dose adjustment
Renal impairment increases thiotepa and TEPA exposure, so caution and consideration of dose reduction are warranted in moderate-to-severe impairment; no rigidly validated CrCl band exists. Exposure is best managed by clinical PK awareness rather than a fixed formula.
Dialyzability & ESKD dosing
Small, lipophilic, rapidly cleared; specific HD-removal data are limited and dialysis is not used for drug clearance. In ESKD, exposure considerations argue for cautious dosing rather than reliance on dialysis.
Differential diagnosis
Hemorrhagic cystitis (urothelial bleeding, dysuria, bland renal function) vs BK/JC virus-associated HC (later onset, viruria) vs clot-obstruction post-renal AKI vs true tubular injury. Bladder, not nephron, is the lesion; preserved creatinine with hematuria/dysuria is the giveaway.
Monitoring
- Urinalysis and gross-hematuria assessment during/after conditioning
- BK/JC viruria/viremia when HC is prolonged or late
- Renal function (post-renal obstruction from clots; exposure in CKD)
Key trials & series
- Galli Eur J Haematol 2024 - large cohort linking TBF (thiotepa-busulfan-fludarabine) conditioning to higher HC risk
- TBF and other thiotepa-based conditioning protocols as the principal HC exposure context
Clinical pearls
- Thiotepa's renal-tract toxicity is in the bladder (hemorrhagic cystitis), not the tubule - creatinine is usually normal.
- In transplant HC, always test for BK/JC reactivation; it co-drives bleeding and changes management.
- Renal impairment raises thiotepa/TEPA exposure - dose cautiously even though the kidney is not the target organ.
Where it strikes
Nephron segments
Bladder / Urothelium
Urine storage (outflow, not a nephron segment)
Injury signatures
Hemorrhagic Cystitis
Beyond the kidney
Class-level context for the major non-renal toxicities of alkylators.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression; secondary malignancy risk
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Ifosfamide encephalopathy (chloroacetaldehyde)
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- High-dose cyclophosphamide cardiotoxicity
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRisk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy.Galli E et al. · Eur J Haematol 2024 · PMID 38183299Thiotepa-busulfan-fludarabine conditioning associated with higher hemorrhagic cystitis risk (12-37% HC range).PMIDChemistry, pharmacology and pharmacokinetics of N,N',N"-triethylenethiophosphoramide (ThioTEPA).van Maanen MJ et al. · Cancer Treat Rev 2000 · PMID 10913381Definitive PK/pharmacology review including urinary excretion of thiotepa and TEPA.PMIDAltered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.Ekhart C et al. · Cancer Chemother Pharmacol 2008 · PMID 18431571Renal impairment increases thiotepa/TEPA exposure - evidence for dosing caution.PMIDThrombotic and hemorrhagic complications in children and young adult recipients of Hematopoietic Stem Cell Transplant (HSCT).Kaur D et al. · Thromb Res 2018 · PMID 29787942Hemorrhagic cystitis (and SOS) linked to thiotepa-containing conditioning.PMIDComparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.Yalcin K et al. · J Pediatr Hematol Oncol 2021 · PMID 33625092Busulfan/fludarabine/thiotepa conditioning with hemorrhagic cystitis among early complications.PMIDAnticancer drug-induced kidney disorders.Kintzel PE · Drug Saf 2001 · PMID 11219485Onconephrology context for alkylator urinary-tract and renal toxicity.